Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARS-CoV-2-Specific T Cells for COVID-19 in Cancer Patients
NCT04742595Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2020
- Primary completion
- Sep 2024
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes in coronavirus disease 2019 (COVID-19), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Assessment of feasibility at 3 months and Incidence of adverse events at 3 months. Started Dec 2020; status: completed.
02
Drugs
SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04742595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04742595.